Frankfurt - Delayed Quote EUR

BioVaxys Technology Corp. (5LB.F)

0.0130

-0.0190

(-59.38%)

As of 8:03:14 AM GMT+2. Market Open.

BioVaxys and Sona partner to develop cancer therapeutics

The partnership will explore the use of THT with DPX formulation as a carrier for neoantigens.

Pharmaceutical Technology 5 days ago

BIOV.CN
BioVaxys and Sona Nanotech Enter Research Collaboration

Vancouver, British Columbia, and Halifax, Nova Scotia--(Newsfile Corp. - May 7, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapy™ ("THT"), a phototherm

Newsfile 6 days ago

BVAXF

SNANF
BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce an expansion of the Fields of Use in the current License Agreement to include commercial aquaculture, plus the farm-raised fish market. With this expansion in the Fields of Use, SpayVac-for-Wildlife's markets now include its no-booster fertility-control vaccines for aquaculture as well as overabundant feral/wild/invasive animals, and select production and co

CNW Group 21 days ago

BVAXF
BioVaxys Technology Corp. Announces Revocation of Management Cease Trade Order and Closing of Debt Settlement Transaction

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce the revocation of the management cease trade order (the "MCTO") issued by its principal regulator, the British Columbia Securities Commission (the "BCSC"), on March 3, 2025.

CNW Group last month

BVAXF
BioVaxys Technology Corp. Granted Management Cease Trade Order

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announces that, further to its news release dated February 13, 2025, its principal regulator, the British Columbia Securities Commission (the "BCSC"), has accepted the Company's application for, and has granted, a management cease trade order (the "MCTO") under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

CNW Group 2 months ago

BVAXF
BioVaxys Announces Debt Settlement Agreement, Extension of Private Placement Closing Date and Closing of The Fourth and Final Tranche of Private Placement

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or "Company") announces that it has entered into debt settlement agreements with arm's-length consultants of the Company (the "Consultants") to settle an aggregate of $207,656.50 in debt owed to the Consultants by issuing 4,153,130 common shares in the capital of the Company (each, a "Share") at a deemed value of $0.05 per Share (the "Debt Settlement"). The board of directors of the Company has determined that it is in the best interes

CNW Group 2 months ago

BVAXF
BioVaxys Announces Application for Management Cease Trade Order

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announces that as a result of delays in the completion of its audit, the Company anticipates that it will experience a short-term delay in filing its audited annual financial statements for the year ended October 31, 2024, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the "Required Filings"). Under National Instrument 51-1

CNW Group 2 months ago

BVAXF
BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce, further to its news release of January 10, 2025, an extension of its previously announced non-brokered private placement offering of units of the Company (the "Units") at a price of $0.05 per Unit (the "Private Placement"). Each Unit consists of one (1) common share in the capital of the Company (each, a "Share") and one (1) whole Share purchase warrant (each, a "Warrant"), whereby each Warrant

CNW Group 3 months ago

BVAXF
BioVaxys Developing DPX to be 'Carrier of Choice' for mRNA Vaccines

BioVaxys Technology (BIOV.CN) on Thursday said it is developing its DPX platform to be the "carrier

PREMIUM
MT Newswires 3 months ago

BIOV.CN
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential for its DPX™ non-systemic immune educating platform to address the inherent limitations of lipid nanoparticles ("LNPs") for packaging and delivering mRNA and other polynucleotides. Continued development of DPX-mRNA formulations is one of the Company's objectives, with BioVaxys pursuing collaborations with companies and academic institutions that possess pipelines of promising tu

PR Newswire 3 months ago

BVAXF
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

MIAMI, Jan. 15, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 78th Emerging Growth Conference on January 15 & 16, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp

GlobeNewswire 3 months ago

IPWR

NZAUF

ELRRF
BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage company developing a portfolio of vaccines based on its novel DPX™ immune educating platform to treat a range of cancers, infectious diseases, and immune modulated disorders, is pleased to announce that it has been invited to present on the Emerging Growth Conference at 3:25PM - 3:35PM Eastern Time on Thursday January 16, 2025. This live interactive online event will give existing shar

CNW Group 3 months ago

BVAXF
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 10,750,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $537,500.

CNW Group 3 months ago

BVAXF
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that in anticipation of restarting clinical studies of various DPX formulations and initiating new preclinical studies, it has acquired a 48-kilogram ("kg") supply of GMP-grade lipid to enable production of the Company's DPX antigen packaging delivery platform.

PR Newswire 4 months ago

BVAXF
BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND ANNOUNCES DEBT SETTLEMENT AGREEMENT

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 2,200,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $110,000.

CNW Group 4 months ago

BVAXF
BIOVAXYS ANNOUNCES REPRICING OF PRIVATE PLACEMENT OFFERING

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has reduced the price per unit of the Company ("Unit") in connection with the non-brokered private placement offering (the "Offering") previously announced on November 18, 2024, and has also increased the number of Units offered.

CNW Group 4 months ago

BVAXF
BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized Cancer Vaccine Summit

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) in Boston, MA, that supports further differentiation of its DPX immune educating platform from current aqueous, emulsion, and LNP antigen delivery systems. The study demonstrates that DPX formulations with tumor-derived peptide neoantigens are highly effective vaccines to inhibit or pr

CNW Group 5 months ago

BVAXF
Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

MIAMI, Dec. 04, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 77th Emerging Growth Conference on December 4 & 5, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa

GlobeNewswire 5 months ago

UCAR

OPWEF

BIXT
BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to jointly announce that SpayVac for Wildlife, Inc.'s Madison, Wisconsin laboratory and production facility is now fully able to supply its cutting-edge contraceptive vaccines, including its well-established pZP vaccine ("SpayVac®") and its newest GnRH vaccine for commercial aquaculture and other species.

CNW Group 5 months ago

BVAXF
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technolo

CNW Group 6 months ago

BVAXF

Performance Overview

Return	5LB.F	S&P/TSX Composite index (^GSPTSE)
YTD	-61.19%	+4.05%
1-Year	-70.79%	+15.17%
3-Year	-81.94%	+27.45%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioVaxys Technology Corp. (5LB.F)

BioVaxys and Sona partner to develop cancer therapeutics

BioVaxys and Sona Nanotech Enter Research Collaboration

BioVaxys and SpayVac-for-Wildlife Expand License Agreement Into Commercial Aquaculture

BioVaxys Technology Corp. Announces Revocation of Management Cease Trade Order and Closing of Debt Settlement Transaction

BioVaxys Technology Corp. Granted Management Cease Trade Order

BioVaxys Announces Debt Settlement Agreement, Extension of Private Placement Closing Date and Closing of The Fourth and Final Tranche of Private Placement

BioVaxys Announces Application for Management Cease Trade Order

BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE

BioVaxys Developing DPX to be 'Carrier of Choice' for mRNA Vaccines

BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*

Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now

BioVaxys Technology Corp. to Present at the Emerging Growth Conference on Thursday January 16, 2025

BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

BIOVAXYS ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT AND ANNOUNCES DEBT SETTLEMENT AGREEMENT

BIOVAXYS ANNOUNCES REPRICING OF PRIVATE PLACEMENT OFFERING

BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized Cancer Vaccine Summit

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY

BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium

Performance Overview